Erudio Healtherudio.com
Clinical trial · no report yet · Phase not applicable
RADICALPC trial: what clinicians have said so far
A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
- NCT03127631 ↗
- Active, not recruiting
- McMaster University
- Standard size, estimated: 151–300 verified statements
We haven't built an HCP commentary report on RADICALPC (prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on RADICALPC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 9 posts on X | |
| 2 podcast episodes |
The trial
ClinicalTrials.gov- Official title
- The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A Randomized Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
- Phase
- Phase not applicable
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer; Cardiovascular Disease
- Interventions
- Nutrition; Exercise; Smoking cessation; Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin); ACE inhibitor
- Arms
- Randomized - Intervention · Active comparator
- Randomized - Control · No intervention
- Enrollment
- 5,000 (estimated)
- Primary outcomes
- Hierarchical composite of cardiovascular death, myocardial infarction, stroke, heart failure, cholesterol control (defined as total cholesterol ≤4mmol/L) and systolic blood pressure control (defined as systolic blood pressure ≤130mmHg).
- Time to the first occurrence of the composite of cardiovascular death, myocardial infarction, stroke, heart failure.
- Sponsor
- McMaster University with Prostate Cancer Canada, Canadian Cancer Society (CCS), Tolmar Inc.
- Start
- Oct 21, 2015
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03127631 · updated Jul 2, 2026
Publications
linked from the registry- Leong DP, Higano C, Cano Garcia C, Fradet V, Siemens DR, Niazi T, Shayegan B, Guha A, Cirne F, Selvanayagam JB, Violette PD, Valle FH, Lavallee LT, Duceppe E, Anderson P, Xavier D, Lopez-Lopez JP, Villareal Trujillo N, Galapo Kann A, Piccoli RK, Mourtzakis M, Sarid D, Narasimha S, Luke PPW, Hajjar LA, Lukka H, Klotz L, Balasubramanian K, Mian R, Agapay S, Rangarajan S, Karampatos S, Ng KKH, Avezum A, Devereaux PJ, Pinthus JH; RADICAL PC Investigators. Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial. JAMA Intern Med. 2026 Aug 30. doi: 10.1001/jamainternmed.2026.4773. Online ahead of print. PubMed 42669035
- Dahan J, Pinthus J, Delouya G, Taussky D, Duceppe E, de Jesus A, Leong D. Investigation of association between clinically significant prostate cancer, obesity and platelet to-lymphocyte ratio and neutrophil -to-lymphocyte ratio. BMC Urol. 2024 Oct 16;24(1):226. doi: 10.1186/s12894-024-01617-2. PubMed 39407194
- Savija N, Leong DP, Pinthus J, Karampatos S, Shayegan B, Mian R, Rangarajan S, Fradet V, de Souza RJ, Mente A, Dehghan M. Development and Comparability of a Short Food-Frequency Questionnaire to Assess Diet in Prostate Cancer Patients: The Role of Androgen Deprivation Therapy in CArdiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC) Substudy. Curr Dev Nutr. 2021 Aug 12;5(11):nzab106. doi: 10.1093/cdn/nzab106. eCollection 2021 Nov. PubMed 34870071